Biologic drugs are some of the most expensive medications on the market. When a patent expires, you might expect prices to drop like they do for generic pills. But that hasn’t happened as quickly or as dramatically with biologics. Instead, we have biosimilars, which are FDA-approved versions of biologic drugs that are highly similar to reference products in safety, purity, and potency. While these drugs can cost 10-33% less than their brand-name counterparts, getting your insurance to cover them-and at a lower out-of-pocket cost-is a different story.
The gap between what is available and what patients actually use is widening. As of 2025, the FDA has approved over 70 biosimilars, yet only about 40 are commercially available. Even more telling, major Pharmacy Benefit Managers (PBMs) often place biosimilars on the same high-cost tiers as the original brand drugs. This means you pay almost the same amount regardless of which version you take. Understanding how biosimilar insurance coverage works, specifically regarding prior authorization and tier placement, is crucial for managing healthcare costs in 2026.
How Biosimilars Differ from Generic Drugs
To understand why coverage is so tricky, you first need to know what you’re dealing with. A generic drug is an exact molecular copy of a brand-name small-molecule drug. Think of it like copying a recipe for cookies; if you follow the ingredients exactly, the result is identical.
Biosimilars are different. They are made from living organisms-cells, bacteria, or yeast. You cannot just copy-paste the process because biological manufacturing is complex and sensitive to tiny changes in temperature, pressure, or nutrient supply. The FDA requires biosimilars to demonstrate "high similarity" to the reference product, but they don’t have to be identical. This scientific nuance leads insurers to treat them differently than simple generics.
- Generics: Exact chemical copies. Usually placed on the lowest copay tier (Tier 1).
- Biosimilars: Highly similar biological products. Often placed on specialty tiers (Tier 4 or 5) alongside brand names.
This distinction matters because insurers argue that since biosimilars aren't identical, they shouldn't automatically get the cheapest pricing structure. However, clinical data consistently shows they perform just as well as the reference products for most conditions.
The Reality of Formulary Tiers and Cost-Sharing
Your insurance plan’s formulary is the list of drugs it covers. Most plans use a tiered system where higher tiers mean higher costs for you. Specialty biologics usually sit on Tier 4 or 5, requiring coinsurance-a percentage of the drug’s cost-rather than a flat copay.
Here is the frustrating part: even when a cheaper biosimilar exists, insurers rarely put it on a lower tier. According to a November 2024 report by the Department of Health and Human Services Office of Inspector General (OIG), 99% of Medicare Part D formularies placed Humira (adalimumab) and its biosimilars on the same cost-sharing tier in 2025. Almost no plans used preferential tier placement to encourage patients to switch to the cheaper option.
| Feature | Reference Biologic (Brand) | Biosimilar |
|---|---|---|
| Average List Price | $4,000 - $5,000 per dose | 10-33% lower than reference |
| Typical Tier Placement | Tier 4 or 5 (Specialty) | Tier 4 or 5 (Specialty) |
| Patient Cost Structure | 25-33% Coinsurance | 25-33% Coinsurance (Same tier) |
| Prior Authorization Required? | Yes (98.5% of plans) | Yes (Often stricter) |
| Pharmacist Substitution Allowed? | No | Only if designated "Interchangeable" |
When both drugs are on the same tier, the financial incentive for you to choose the biosimilar vanishes. For example, a Medicare Rights Center analysis found that patients paying out-of-pocket for Humira paid an average of $1,200 monthly, while those taking biosimilars paid $1,150. That $50 difference isn’t enough to sway most people, especially if they trust the brand name they’ve been using for years.
Prior Authorization: The Administrative Hurdle
Even if your plan covers a biosimilar, you likely won’t get it without jumping through hoops. Prior authorization (PA) is a process where your doctor must prove to the insurer that you need a specific drug before they will pay for it.
For biologics, this is standard. In 2025, 98.5% of plans required prior authorization for Humira and its biosimilars. But here’s the catch: insurers rarely make the PA process easier for biosimilars. In fact, many plans apply the same strict documentation requirements to both. Your provider needs to submit treatment history, proof that other therapies failed, and justification for dosing. Approval takes anywhere from 3 to 14 business days.
This creates a massive burden on healthcare providers. A 2024 survey by the Alliance for Patient Access found that 78% of rheumatologists spend 3-5 hours every week just managing these requests. More importantly, it delays care. One case study documented a patient with severe rheumatoid arthritis who waited 28 days for treatment because the insurer mandated a trial of a biosimilar before approving the reference product. These delays can worsen health outcomes.
Step Therapy and Forced Switching
Some insurers use a strategy called step therapy, also known as "fail-first." This means you must try a cheaper medication (often a biosimilar) and fail before the insurer will cover the more expensive reference biologic. While this sounds like it helps you save money, it often backfires.
Step therapy protocols commonly mandate 60-90 day trials. If the biosimilar doesn’t work-or if side effects occur-you go through the entire prior authorization process again to switch back to the brand. This cycle disrupts treatment continuity and frustrates both patients and doctors. It also ignores the reality that for many chronic conditions, starting with the most effective, familiar drug is medically preferable.
However, the landscape is shifting. Some PBMs are now doing the opposite. In 2025, Express Scripts excluded Humira entirely from 100% of its commercial formularies. Instead, they placed multiple biosimilars on preferred specialty tiers (Tier 3) with 25% coinsurance, compared to the standard 33% for non-preferred drugs. This aggressive exclusion strategy forces patients toward biosimilars by simply not covering the brand anymore.
Why Adoption Remains Low Despite Savings
If biosimilars save money, why isn’t everyone using them? The U.S. biosimilar market reached $15.3 billion in 2024, capturing only 18% of the total biologics market. Compare this to Europe, where biosimilars hold over 80% market share. The difference lies in policy.
In Europe, governments aggressively negotiate prices and mandate substitution. In the U.S., the system relies on voluntary adoption by private insurers and PBMs. Several factors keep U.S. adoption low:
- Lack of Financial Incentive: With tier alignment, patients see minimal savings ($50/month).
- Provider Inertia: Doctors prescribe what they know. Switching requires retraining and new monitoring protocols.
- Complex Substitution Rules: Only biosimilars with an "interchangeable" designation can be substituted by pharmacists without a new prescription. This applies to very few products, such as certain formulations of adalimumab-adbm (Cyltezo).
- PBM Practices: Critics argue that PBMs maintain high rebates from brand manufacturers, giving them little reason to push biosimilars unless forced by competition or regulation.
The Congressional Budget Office (CBO) estimates that biosimilars could save the U.S. healthcare system $54 billion over the next decade. However, under current coverage patterns, they project only $1.8 billion in annual federal savings by 2030. To hit the higher savings target, adoption barriers must be removed.
What’s Changing in 2026?
Regulatory pressure is mounting. Following the OIG’s 2024 report, CMS expanded its formulary monitoring to include tier placement comparisons. The goal is to ensure plans aren’t artificially suppressing biosimilar use. Additionally, the Inflation Reduction Act includes provisions that may penalize discriminatory tiering practices.
Industry analysts predict biosimilar adoption will accelerate to 40% market share by 2027. This growth is driven by:
- Exclusionary Formularies: More PBMs excluding top-selling brands like Humira to force biosimilar uptake.
- Increased Competition: Over 70 FDA-approved biosimilars provide more options for insurers to negotiate.
- Transparency Laws: New reporting requirements force plans to disclose how they cover biosimils versus reference products.
For patients, this means you’ll likely see more biosimilars appearing on your plan’s preferred list. However, you should still check your specific formulary. Just because a biosimilar exists doesn’t mean your plan covers it, or that it’s on a lower tier than the brand.
How to Navigate Your Coverage
Don’t assume your insurance treats biosimilars fairly. Take these steps to manage your costs:
- Check the Formulary: Look up both the brand name and the biosimilar on your insurer’s website. Note the tier number for each.
- Ask About Interchangeability: Ask your pharmacist if the biosimilar is designated "interchangeable." If yes, they may swap it for you without a new prescription, depending on state law.
- Request a Pre-Authorization Override: If you’re stuck on step therapy, ask your doctor to submit a medical necessity letter arguing why the reference product is essential for your condition.
- Use Patient Assistance Programs: Both brand manufacturers and biosimilar makers offer copay cards. Compare the out-of-pocket costs after applying these discounts.
The gap between biosimilar potential and reality is closing, but slowly. Until insurers align tiers and simplify prior authorization, patients will continue to face unnecessary administrative burdens and missed savings opportunities. Stay informed, read your plan documents, and advocate for coverage that prioritizes value over brand loyalty.
Are biosimilars covered by Medicare Part D?
Yes, most Medicare Part D plans cover biosimilars. However, coverage varies significantly by plan. In 2025, 78% of formularies included available biosimilars alongside reference products. But be aware that many plans place them on the same high-cost tiers as brand-name biologics, meaning your out-of-pocket costs may not decrease substantially.
What is the difference between a biosimilar and a generic drug?
Generic drugs are exact molecular copies of small-molecule brand drugs. Biosimilars are highly similar versions of complex biologic drugs made from living organisms. Because biological manufacturing is variable, biosimilars cannot be identical copies. They must demonstrate high similarity in safety, purity, and potency, but minor differences are allowed. This complexity often leads insurers to treat them differently than generics.
Why do insurers require prior authorization for biosimilars?
Prior authorization ensures that patients receive appropriate care and that insurers verify medical necessity. For biosimilars, this process is often as strict as for brand-name drugs. Insurers use it to control costs and manage utilization. However, critics argue that requiring prior authorization for both brands and biosimilars creates unnecessary administrative burdens for doctors and delays patient access to treatment.
Can my pharmacist substitute a biosimilar for my brand-name biologic?
Only if the biosimilar has an "interchangeable" designation from the FDA and your state allows pharmacist substitution. As of 2025, very few biosimilars have this status. For example, adalimumab-adbm (Cyltezo) is interchangeable, but only for specific low-concentration formulations of Humira. Without this designation, you need a new prescription from your doctor to switch.
How much can biosimilars save me?
Biosimilars typically cost 10-33% less than reference biologics. However, your actual savings depend on your insurance plan’s tier placement. If both drugs are on the same tier, you might save only $50-$100 per month. If the biosimilar is on a lower tier or preferred specialty tier, savings can be significant, potentially reducing your coinsurance from 33% to 25% or lowering your fixed copay.
